8-K: TScan Therapeutics Stockholders Elect Class I Directors and Ratify Auditor at 2025 Annual Meeting

TScan Therapeutics, Inc. announced the results of its 2025 annual meeting of stockholders, where Class I directors were elected and Deloitte & Touche LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.

Summary

• TScan Therapeutics, Inc. held its 2025 annual meeting of stockholders on June 30, 2025.
• Stockholders elected Stephen Biggar, M.D., Ph.D., Gavin MacBeath, Ph.D., and Garry Nicholson as Class I directors, each to serve a three-year term ending at the annual meeting in 2028.
• The voting results for Stephen Biggar were 31,050,072 votes For, 460,919 votes Withheld, and 14,313,890 Broker Non-Votes.
• The voting results for Gavin MacBeath were 31,204,939 votes For, 306,052 votes Withheld, and 14,313,890 Broker Non-Votes.
• The voting results for Garry Nicholson were 25,650,072 votes For, 5,860,919 votes Withheld, and 14,313,890 Broker Non-Votes.
• Stockholders ratified the selection of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The voting results for the auditor ratification were 45,724,929 votes For, 64,187 votes Against, and 35,765 Abstain.

Sentiment

Score: 7

Explanation: The document reports on the successful completion of routine corporate governance matters, with all proposals passing as expected. This indicates stable operations and adherence to standard procedures, which is a positive sign for corporate stability.

Positives

• All proposed Class I directors were successfully elected by stockholders.
• The appointment of Deloitte & Touche LLP as the independent auditor was overwhelmingly ratified by stockholders, indicating strong confidence in the company's financial oversight.

Future Outlook

The document does not provide specific forward-looking statements or financial guidance beyond the terms of the elected directors and the auditor's engagement period.

Management Comments

• Gavin MacBeath signed the report as Chief Executive Officer on behalf of TScan Therapeutics, Inc.

Industry Context

This 8-K filing details routine corporate governance matters, specifically the outcomes of an annual stockholder meeting. Such events are standard for publicly traded companies across all industries, ensuring compliance with regulatory requirements and shareholder engagement on key corporate decisions like board composition and auditor selection.

Comparison to Industry Standards

• The election of directors for multi-year terms and the ratification of an independent accounting firm are standard corporate governance practices consistent with U.S. public company norms.
• The voting percentages, particularly the high 'For' votes for the auditor ratification (over 99% of votes cast), are typical for routine proposals in well-governed companies, similar to outcomes seen in companies like Pfizer or Moderna for their annual meeting proposals.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Exercised their voting rights to elect directors and ratify the auditor, directly influencing corporate governance.
• Management: The elected directors will provide strategic guidance and oversight to the management team.
• Employees: The stability of the board and proper financial oversight contribute to overall company stability, which indirectly benefits employees.

Next Steps

• The elected Class I directors will serve their three-year terms until the 2028 annual meeting of stockholders.
• Deloitte & Touche LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

TScan Therapeutics, TCRX, Annual Meeting, Stockholders, Board of Directors, Director Election, Independent Auditor, Deloitte & Touche LLP, Corporate Governance, SEC Filing, 8-K